Today: 9 April 2026
Rivian stock slips in premarket after UBS turns bearish — what could move RIVN next
15 January 2026
1 min read

Rivian stock slips in premarket after UBS turns bearish — what could move RIVN next

NEW YORK, Jan 15, 2026, 05:00 ET — Premarket

Rivian Automotive’s shares eased 0.2% to $17.47 in premarket trading on Thursday, after the stock sank 7.2% in the previous session. The slide followed a UBS downgrade that questioned whether optimism around the EV maker’s next model and software push is already in the price. Public

UBS analyst Joseph Spak cut Rivian to Sell from Hold and lifted his 12-month price target — his forecast for where the stock could trade — to $15 from $13, Barron’s reported. Spak wrote the stock had gone “too far too fast” and warned that expectations for the company’s R2 launch could set it up for disappointment. Rivian had climbed 44% over the past three months, and about 30% of analysts now rate the stock a sell, Barron’s said. Barron’s

The downgrades come as investors wait for Rivian’s next hard checkpoint: fourth-quarter and full-year results due Feb. 12 after markets close. Rivian delivered 42,247 vehicles in 2025, down about 18% from a year earlier, and is preparing to start delivering its lower-cost R2 SUV in the first half of 2026, Reuters reported. Reuters

Earlier this week, Wolfe Research analyst Emmanuel Rosner also downgraded the stock to Sell with a $16 target, arguing the company faces a near-term “catalyst vacuum” before autonomy-related benefits show up later. Rosner said Rivian needs a stronger focus on artificial intelligence, similar to Tesla, especially in autonomous driving and subscription-based services, Barron’s wrote. Barron’s

Rivian has also been reshuffling its leadership as it gears up for the R2, hiring Greg Revelle as chief customer officer to oversee sales, marketing and operations, WardsAuto reported. WardsAuto

Traders were busy in derivatives on Wednesday. Rivian options volume was running at roughly three times the daily average, with calls — contracts that profit if a stock rises — outnumbering puts by about 1.5 to 1, Charles Schwab’s daily options update said. Schwab Brokerage

The stock swung through $17.07 to $18.25 on Wednesday before finishing at $17.50. It traded lower again early Thursday, but the premarket move was modest after the prior session’s drop. StockAnalysis

But the downside case is not hard to sketch: any slip on quality or execution can hit sentiment fast in this name. Rivian is recalling 19,641 previously serviced R1S and R1T vehicles in the U.S. over an improperly reassembled rear toe link, the U.S. safety regulator said last week. The company was aware of one crash with minor injuries linked to the issue, Reuters reported. Reuters

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:12 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
MongoDB stock bounces in premarket after 6% slide; traders eye MongoDB.local and earnings clock
Previous Story

MongoDB stock bounces in premarket after 6% slide; traders eye MongoDB.local and earnings clock

Twilio stock steadies in premarket after 5% drop as tech nerves linger
Next Story

Twilio stock steadies in premarket after 5% drop as tech nerves linger

Go toTop